
    
      This is an open label, extension study for subjects completing the ZPU-003 Ext 1 study and an
      off-drug interval (menses), prior to the start of the first 16-week dosing cycle. Subjects
      will receive a 50 mg ProellexÂ® daily dose. Total study participation for ZPU-003 Ext 2
      (Extension 2) may be up to three 4 month drug cycles separated by off drug intervals.
    
  